UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
N-CSR
CERTIFIED
SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT
COMPANIES
INVESTMENT
COMPANY ACT FILE NUMBER 811-22684
DAXOR
CORPORATION
(Exact
name of registrant as specified in charter)
109
Meco Lane
Oak
Ridge, TN 37830
(Address
of principal executive offices) (Zip code)
Michael
Feldschuh
109
Meco Lane
Oak
Ridge, TN 37830
(Name
and address of agent for service)
REGISTRANT’S
TELEPHONE NUMBER, INCLUDING AREA CODE: 212-330-8500
DATE
OF FISCAL YEAR END: DECEMBER 31
DATE
OF REPORTING PERIOD: JANUARY 1, 2023 to JUNE 30, 2023
Daxor
Corporation
Financial
Statements (Unaudited)
For
the Six Months Ended
June
30, 2023
Table
of Contents
Exhibits
Daxor
Corporation
August
28, 2023
Dear
Fellow Shareholders:
There
are rare times in a business when multiple efforts converge leading to opportunity that is greater than the sum of its parts. For Daxor,
now is just such a time. The company is focused on profoundly improving outcomes for tens of millions of patients as well as the hospital
systems and the payers which support the system by solving a central problem of medicine – providing highly accurate, convenient,
and rapid knowledge of patient blood volume. Managing blood volume is the cornerstone of care for some of the largest areas of patient
care – heart failure, sepsis, post-surgical blood loss and syncope to cite a few, but this urgent medical need has been hampered
using surrogate markers, not direct measurement, of the blood volume. Many of these markers are costly, some are invasive, and none are
accurate – in contrast to Daxor’s 98% accurate system. Care teams cannot effectively treat what they do not correctly diagnose,
so a rapid accurate diagnostic is a game-changer. Every metric that matters is impacted from this first principle of accurate diagnosis
– patients receiving optimal care are treated more quickly with better outcomes, have shorter lengths of stay in the hospital,
suffer fewer costly readmissions, and have lower mortality and fewer complications in the long run. This leads to better results for
patients, hospitals, and insurers on both a health and economic level.
So,
what is the convergence of efforts that has Daxor Management so excited? A new portable point-of-care analyzer capable of giving blood
volume results in as little as 15 minutes at the patient bedside to replace the lab-based BVA-100® (Blood Volume Analyzer) in current
use, compelling new clinical and health economic outcomes, additional funding from the U.S. Department of Defense (DoD) and National
Institutes of Health (NIH) for further technology development and clinical trials, and partnerships with medical societies and key opinion
leaders to shape the discourse and guidelines on the need for direct blood volume analysis to become the standard of care. These efforts
are happening as Daxor continues to expand its commercial adoption among leading academic medical centers with innovations such as our
new reference lab service and growth of our intellectual property (IP) portfolio with more than half a dozen patents pending. It is the
convergence of these efforts leading to the growing awareness that one of the thorniest problems in medicine has a new solution which
is a paradigm shift benefiting all parts of the healthcare system.
It
is my pleasure to report on Daxor’s results for the mid-year ended June 30, 2023. For the fourth year in a row our operating business
is experiencing continued growth and development — increasing revenues from commercialization, great progress in research and development
for our next-generation systems set for potential approval at the end of this year, and a growing body of clinical evidence from leading
research centers of the unique value of our diagnostic to save lives and vastly improve patient health and hospital economic outcomes.
The opportunity for our business is to scale into the total serviceable market of more than ten million tests per year in the United
States alone through organic growth, partnership, and joint ventures.
I
have written in the past that to realize that promise and the enormous market potential for our products requires the company to execute
on three key areas of performance: strong commercialization, next-generation product development, and continued clinical outcomes. I
am pleased to report that in 2023 we continue building on our focus in each of these key areas.
As
of June 30, 2023, Daxor’s net assets were $30,359,013 or $6.33 per share as compared to $28,969,469, or $6.75 per share on December
31, 2022. This increase in net assets is primarily due to the public offering during the six-month period ended June 30, 2023, whereby
Daxor raised $4.1 million, net to Daxor by selling 464,599 shares at $9.75. The net asset value per share was adjusted to account for
the addition of 464,599 shares to the float of the stock. For the six-month period ended June 30, 2023, Daxor had net dividend income
of $77,990, and net realized gains on investment activity of $603,661. There was a net decrease in the unrealized appreciation on investments,
of $760,280 as we sold positions during 2023 and prior period’s significant unrealized gains unwound into the gains for the period.
Included in the Net Decrease in Net Assets Resulting from Operations of $3,037,182 is non-cash stock-based compensation expense of $324,273
in an effort to provide incentive to employees, officers, agents, and consultants through proprietary interest in the company. There
was a net realized loss of $2,445,170 from the operating division relating to spending on research, development, sales and overhead as
the Company continues to invest judiciously in research and development for our 2023 product launch, ramping the commercial sales teams,
as well as production facilities for our next generation blood volume analyzers.
Focusing
further on the operating division financial performance, the Company is pleased to report a 20.64 percent increase in the unaudited revenues
of our single-use test kits for the six-month period ended June 30, 2023, as compared to the six-month period ended June 30, 2022. Revenue
growth was driven by a combination of the sale and leasing of our capital equipment to hospitals and orders for our single-use blood
volume diagnostics kits for heart failure management, critical care use, among other indications. Daxor added eight new accounts during
the six-month period ended June 30, 2023. Many of these new accounts are just beginning to ramp up as they integrate our diagnostic into
their treatment protocols and the need for our product has never been greater – heart failure patients are set to rise from the
current 6 million to more than 8 million in the next six years as the baby boom generation ages and hospitals are under increasing pressure
to improve outcomes and contain costs.
In
June of this year Daxor launched its new ezBVA Lab service for clinical sites that wish to perform BVA testing using Daxor’s lab
services without the need for an on-site analyzer. This new service, priced at $965 per test, represents a significant value for customers
and is a premium to the sale of a test kit which sells for $385. The company is paid for performing the lab analysis and the customer
requires little overhead and reduced labor to administer the test. This new service has a building pipeline of customers in the on-boarding
process, and management anticipates signing new customers at a rate of approximately one a month going forward given the initial demand
for the product. This effort is a faster sales cycle and has attractive margins for the company and is complementary to the launch of
our next generation analyzer which management anticipates being priced at a similar level. Increasing the value of our offerings and
the associated revenue is a priority for the company to drive growth in both absolute terms and on a profit per unit sold metric.
Daxor
anticipates submission and review by the FDA of its next generation analyzer under a 510-K/CLIA dual submission pathway by the end of
this year. Validation has been underway at several sites since Q1, and the study has been proceeding according to plan although enrollment
at some centers has been slower than Management initially anticipated. This point-of-care blood volume analysis system, developed under
multiple contracts with the U.S. DoD, as well as grants from the NIH, is a significant leap forward in our market-leading technology.
Daxor developed the new analyzer under contract with the U.S. DoD in 2022, and successfully demonstrated a manufacture-ready prototype
that was specified to be equivalent to the current 510(k) cleared BVA-100 unit in terms of accuracy and capabilities. This new system
has been measured to be three times faster, simpler, battery powered and capable of being a full point-of-care CLIA-waived device. Our
development for a model utilizing a novel fluorescent marker is also ongoing under U.S. DoD contract for use in new care settings beyond
our current systems. Daxor met with the FDA in the fall of 2022 to discuss its pre-submission data for a 510(k)/CLIA dual pathway. Management
was able to ask questions and receive guidance from the agency on a validation plan and application pathway to satisfy regulatory requirements.
Daxor is currently executing the validation of the prototype system with clinical partners to satisfy FDA standards and intends to submit
its application with a goal of receiving approval by the end of 2023. Driving this important project is our Vice President of Development
and Operations, Linda Cooper - a seasoned professional with a background in bioengineering as well as extensive regulatory experience
with the FDA. For us, it is no exaggeration that this next generation analyzer is our most important product launch in twenty years and
has the potential to deliver a level of speed, access, and accuracy to fluid and blood volume management that can broadly change medicine.
Management
anticipates that upon approval there will be significant interest and uptake of the new system based upon preliminary discussions with
clinicians advising Daxor in the development of the technology as well as an increase in disposable kit sales driven by the speed and
convenience of the new system. Daxor’s next generation devices will also be eligible for Phase III funding awards and acquisition
by branches of the military for their deployment to aid in combat casualty care as well as further development contracts.
Daxor
recently received and is executing a new $1.1 million contract from the U.S. DoD for additional capabilities to its next-generation analyzer
this year. This two-year contract is just one of several pending applications for contract work with the U.S. DoD which are under consideration,
in addition to grant proposals for substantial research studies under review with agencies at the NIH. These contracts provide important
sources of non-dilutive funding, further technology development, and additional clinical validation which drives broader adoption of
our diagnostic. Management anticipates announcing the results of several of these efforts in Q3 and will continue to build upon successful
Phase I funded efforts toward the larger Phase II awards which commonly follow.
Equally
important is the progress that Daxor has made in the area of clinical outcomes utilizing our blood volume analyzer. In Q2 the results
of a pilot Randomized Control Trial (RCT) in heart failure patients with BVA guided treatment was published in the prestigious Journal
of the American College of Cardiology-Heart Failure by researchers from the Duke Clinical Research Institute. This RCT documented
that an astonishing 68% of heart failure patients were misdiagnosed regarding their volume status and that care teams were ineffective
at adjusting these derangements prior to discharge. The researchers citing the outcomes called for funding of a large-scale trial centered
around BVA technology based upon their findings. This trial is in addition to Phase I RCT work at two Veterans Administration hospitals
under NIH funding which completed enrollment in Q2 and will report its findings shortly as a prelude to making an anticipated Phase II
application. In the first half of 2023, over half a dozen new research studies on BVA were published in peer-reviewed journals or at
society conferences. Importantly, these studies highlighted that BVA can reduce hospital length of stay by 2.5 days on average for heart
failure patients, a significant savings, while also improving clinical outcomes. Data on the value of BVA for use in Left Ventricular
Assist Device (LVAD) patients and its superiority to pressure-based cardiac implantable devices are also highlights of data that researchers
from a variety of institutions published. About recognition and awareness of these developments, a landmark session at the Heart Failure
Society of America in 2023 marks the second year in a row that the Annual Meeting will focus on blood volume measurement to improve heart
failure care. Last year’s meeting was attended by hundreds of physicians which posited that Daxor’s BVA provided uniquely
valuable data for congestion management, superior utility to existing standards of care of pressure-based measures, and that further
study and adoption of it was supported by the growing body of evidence. Sessions of this nature led by key opinion leaders - comparing
volume versus pressure measures - represents the growing awareness and substantial need for BVA as an innovative diagnostic to improve
heart failure care. Management is incredibly pleased at the strong and growing reception that our technology is receiving at these events
at special sessions that are not sponsored by Daxor in any way.
The
Company also announced in August 2021 that a promising research letter on the use of Daxor’s BVA-100 analyzer on six COVID-19 patients
at NYU Medical Center had been published in the prestigious Journal of Critical Care. Daxor launched a prospective multi-center
trial on the back of that data which has been expanded to incorporate not only COVID patients but sepsis patients as well. The COVID
arm has completed enrollment and the sepsis comparator arm also completed enrollment at the end of Q2. We anticipate publication to follow
shortly, and Management looks forward to sharing the results of the multi-center trial when they become available. Sepsis is a leading
cause of death in hospitals and an intense area of focus for health system improvements. All data shows that individualized fluid management
holds the key to improving outcomes, something that BVA can uniquely do compared to the existing surrogate markers. A substantial expansion
of the Company’s revenue in critical care medicine could be driven by a combination of the new data, new funding opportunities
the data will open, as well as our next-generation analyzer which promises a speedy workflow which is critical to the needs of this specialty.
The
strong trend of healthcare is toward individualized care and cost-effectiveness. Our BVA diagnostic is a non-invasive, inexpensive, and
rapid blood test which allows care teams to solve the significant challenge of accurately managing the fluid levels of patients, whether
it is in the heart failure clinic (outpatient) or the hospitalized heart failure patient or in the ICU, and studies published and presented
are proving just how exciting the potential for this approach is. Reducing mortality, lowering complications, reducing hospital resource
use and length of stay with a non-invasive and 98% accurate test is achievable with our patented technology. In the competitive area
of healthcare, having achieved reimbursement for our technology for both inpatient and outpatient use is a strong competitive advantage
that will drive BVA adoption in step with our increasing clinical evidence and commercial teams. Just as exciting is the next generation
of products that are in our development pipeline slated for completion this year which should further enhance the accessibility of our
test and open it up to both government as well as civilian hospital systems on an international scale.
Daxor
has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012. See the Notes to the Financial
Statements of Form N-CSR for further information on Daxor’s strategies and goals regarding its investments in publicly traded securities
to help fund its diagnostic operations. Because of its significant holding of publicly traded securities, the SEC currently classifies
Daxor as a closed-end investment management company with a fully owned medical operating division; however, the primary focus of management
is on our operational objectives. Daxor anticipates that as the value of the operating company continues to increase as a percentage
of assets owned, it will be eligible to file under its previous designation as an operating company and report as an operating company
and will take steps to accomplish this result.
Any
shareholder who is interested in learning more about our medical instrumentation and biotechnology operations should visit our website
at www.daxor.com or contact our investor relations representative Bret Shapiro of CORE IR at 516-222-2560 for more detailed information.
We periodically issue press releases regarding research reports and placements of the BVA-100 Blood Volume Analyzer in hospitals.
To
sign up for electronic delivery of shareholder reports and prospectuses, please send an email to info@daxor.com. If you do not
hold your account directly with Daxor, please contact the firm that holds your account about electronic delivery.
Cordially
Yours,
Michael
Feldschuh
CEO
and President
Item
1. Schedule of Investments
Daxor
Corporation
Schedule
of Investments
June
30, 2023 (Unaudited)
| | |
Shares | | |
Fair Value | |
| Common Stock - (United States) – 8.62% | |
| | | |
| | |
| Industrials – 0.01% | |
| | | |
| | |
| Wabtec | |
| 13 | | |
$ | 1,426 | |
| | |
| | | |
| | |
| Materials – 0.36% | |
| | | |
| | |
| Enbridge Inc. | |
| 2,952 | | |
| 109,667 | |
| | |
| | | |
| | |
| Utilities – 8.25% | |
| | | |
| | |
| Electric Utilities – 8.25% | |
| | | |
| | |
| Avangrid, Inc. | |
| 7,000 | | |
| 263,760 | |
| Avista Corporation | |
| 6,000 | | |
| 235,620 | |
| CenterPoint Energy, Inc. | |
| 1,000 | | |
| 29,150 | |
| Centrus Energy Corp. | |
| 1 | | |
| 33 | |
| CMS Energy Corporation | |
| 3,500 | | |
| 205,625 | |
| DTE Energy Company | |
| 2,000 | | |
| 220,040 | |
| Edison International | |
| 4,000 | | |
| 277,800 | |
| Entergy Corporation | |
| 3,500 | | |
| 340,795 | |
| Evergy Inc. | |
| 4,297 | | |
| 251,031 | |
| Eversource Energy | |
| 2,000 | | |
| 141,840 | |
| Exelon Corporation | |
| 2,100 | | |
| 85,554 | |
| FirstEnergy Corp. | |
| 3,800 | | |
| 147,743 | |
| Pinnacle West Capital Corporation | |
| 3,000 | | |
| 244,380 | |
| Xcel Energy, Inc. | |
| 1,000 | | |
| 62,170 | |
| Total Utilities | |
| | | |
| 2,505,541 | |
| | |
| | | |
| | |
| Total Common Stock (Cost $816,920) – 8.62% | |
| | | |
$ | 2,616,634 | |
| | |
Shares | | |
Fair Value | |
| Preferred Stock - (United States) – 1.16% | |
| | | |
| | |
| | |
| | | |
| | |
| Banking – 1.16% | |
| | | |
| | |
| Bank of America Corp 7.250% Series L | |
| 300 | | |
$ | 351,546 | |
| | |
| | | |
| | |
| Total Preferred Stock (Cost $193,985) – 1.16% | |
| | | |
$ | 351,546 | |
| | |
| | | |
| | |
| Money Market – UBS Select Prime Institutional Fund – (Cost $1,360,081) – 4.48% | |
| | | |
$ | 1,360,081 | |
| | |
| | | |
| | |
| Total Investments in Securities (Cost $2,370,956) – 14.26% | |
| | | |
$ | 4,328,261 | |
| | |
| | | |
| | |
| Investment in Operating Division (Cost $3,118,857) - (United States) – 85.64% (1) | |
| | | |
$ | 26,000,000 | |
| | |
| | | |
| | |
| Dividends receivable – 0.04% | |
| | | |
$ | 10,943 | |
| | |
| | | |
| | |
| Other Assets – 0.06% | |
| | | |
$ | 19,809 | |
| | |
| | | |
| | |
| Total Assets – 100.00% | |
| | | |
$ | 30,359,013 | |
| Total Liabilities - (0%) | |
| | | |
$ | - | |
| Net Assets - 100% | |
| | | |
$ | 30,359,013 | |
(1)
The Fair Value of the Operating Division was determined by using significant unobservable inputs.
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Schedule
of Investments – (Unaudited) (Continued)
June
30, 2023
At
June 30, 2023, the net unrealized appreciation on investment in securities, options and securities borrowed of $1,957,274 was composed
of the following:
| Aggregate gross unrealized appreciation for which there was an excess of value over cost | |
$ | 1,962,453 | |
| Aggregate gross unrealized depreciation for which there was an excess of cost over value | |
| (5,179 | ) |
| Net unrealized appreciation | |
$ | 1,957,274 | |
At
June 30, 2023, the net unrealized appreciation on investment in operating division was composed of the following:
| Net unrealized appreciation on investment in operating division | |
$ | 22,881,143 | |
Portfolio
Analysis
June
30, 2023
| | |
Percentage of Net Assets | |
| Common Stock (United States) | |
| |
| Industrials | |
| 0.01 | % |
| Materials | |
| 0.36 | % |
| Electric Utilities | |
| 8.25 | % |
| | |
| | |
| Total Common Stock | |
| 8.62 | % |
| | |
| | |
| Preferred Stock (United States) | |
| | |
| Banking | |
| 1.16 | % |
| | |
| | |
| Money Market | |
| 4.48 | % |
| | |
| | |
| Total Investments in Securities | |
| 14.26 | % |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Summary
of Liabilities
(Unaudited)
June
30, 2023
| Total Liabilities - None | |
| - | | |
| - | |
| | |
| - | | |
$ | - | |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Statement
of Assets and Liabilities (Unaudited)
June
30, 2023
| Assets: | |
| |
| Investments in securities, at fair value (cost of $2,370,986) | |
$ | 4,328,261 | |
| Investment in operating division, at fair value (cost of $3,118,857) | |
| 26,000,000 | |
| Dividends receivable | |
| 10,943 | |
| Prepaid taxes and other assets | |
| 19,809 | |
| Total Assets | |
| 30,359,013 | |
| | |
| | |
| Liabilities: | |
| | |
| Margin loans payable | |
| - | |
| Accounts payable and accrued expenses | |
| - | |
| | |
| | |
| Total Liabilities | |
| - | |
| Commitments (Note 14) | |
| | |
| Net Assets | |
$ | 30,359,013 | |
| | |
| | |
| Net Asset Value, (10,000,000 shares authorized, 5,316,530
issued and 4,792,319 shares outstanding of $0.01 par value capital stock outstanding) | |
$ | 6.33 | |
| Net Assets consist of: | |
| | |
| Capital paid in | |
$ | 13,278,406 | |
| Total distributable earnings | |
| 21,749,179 | |
| Treasury Stock | |
| (4,668,572 | ) |
| Net Assets | |
$ | 30,359,013 | |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Statement
of Operations (Unaudited)
For
the Six Months Ended June 30, 2023
| Investment Income: | |
| | |
| Dividend income (net of foreign withholding taxes of $1,019) | |
$ | 77,990 | |
| Other income | |
| 2,983 | |
| Total Investment Income | |
| 80,973 | |
| | |
| | |
| Expenses: | |
| | |
| Investment administrative charges | |
| 414,847 | |
| Professional fees | |
| 21,200 | |
| Transfer agent fees | |
| 24,469 | |
| Interest expense | |
| 44,466 | |
| Other taxes | |
| 11,384 | |
| Total Expenses | |
| 516,366 | |
| | |
| | |
| Net Investment(Loss) | |
| (435,393 | ) |
| | |
| | |
| Realized and Unrealized Gain (Loss) on Investments and Other items: | |
| | |
| Net realized gain from investments in securities sold | |
| 603,661 | |
| | |
| | |
| Net change in unrealized (depreciation) on investments | |
| (760,280 | ) |
| | |
| | |
| Realized (loss) on investment in operating division | |
| (2,445,170 | ) |
| Net Realized and Unrealized Gain on Investments and Investment in Operating Division | |
| (2,601,789 | ) |
| | |
| | |
| Income tax (benefit) | |
| 0 | |
| | |
| | |
| Net Increase in Net Assets Resulting From Operations | |
$ | (3,037,182 | ) |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Statement
of Changes in Net Assets
| | |
Six Months Ended | | |
| |
| | |
June 30, 2023 | | |
Year Ended | |
| | |
(Unaudited) | | |
December 31, 2022 | |
| Increase/(Decrease) in Net Assets Resulting from Operations | |
| | | |
| | |
| | |
| | | |
| | |
| Net investment (loss) | |
$ | (435,393 | ) | |
$ | (972,974 | ) |
| Net realized income (loss) from investments in securities and securities sold short | |
| 603,661 | | |
| 2,736,375 | |
| Net realized (loss) from options | |
| - | | |
| (56,954 | ) |
| Net change in unrealized (depreciation) on investments, options and securities borrowed | |
| (760,280 | ) | |
| (2,763,895 | ) |
| Net change in unrealized appreciation in operating division | |
| - | | |
| 9,500,000 | |
| Realized (loss) on investment in operating division | |
| (2,445,170 | ) | |
| (3,264,419 | ) |
| Net Increase in Net Assets Resulting From Operations | |
| (3,037,182 | ) | |
| 5,178,133 | |
| | |
| | | |
| | |
| Capital Share Transactions: | |
| | | |
| | |
| Increase in net assets resulting from stock-based compensation | |
| 324,273 | | |
| 786,642 | |
| Proceeds from sale of treasury stock | |
| 4,102,453 | | |
| 1,851,975 | |
| Net Increase in Net Assets Resulting From Capital Share Transactions | |
| 4,426,726 | | |
| 2,638,617 | |
| | |
| | | |
| | |
| Total Net Increase in Net Assets | |
| 1,389,544 | | |
| 7,816,750 | |
| | |
| | | |
| | |
| Net Assets: | |
| | | |
| | |
| | |
| | | |
| | |
| Beginning of Period | |
| 28,969,469 | | |
| 21,152,719 | |
| |
| | | |
| | |
| End of Period (including undistributed net investment income of $4,326,911 in
2023 and $4,223,230 in 2022 included in net assets) | |
$ | 30,359,013 | | |
$ | 28,969,469 | |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Statement
of Cash Flows
For
the Six Months Ended June 30, 2023 (Unaudited)
| Cash flows from operating activities: | |
| |
| Net (decrease) in net assets resulting from operations | |
$ | (3,037,182 | ) |
| Adjustment to reconcile net increase in net assets resulting from operations to net cash used in operating activities: | |
| | |
| Net realized gain from investments in securities sold | |
| (603,661 | ) |
| Net realized (loss) from options | |
| | |
| Net change in unrealized depreciation on investments, options and securities borrowed | |
| 760,280 | |
| Net change in unrealized appreciation in operating division | |
| | |
| Investment in/advances to operating division | |
| (2,445,170 | ) |
| Realized loss on operating division | |
| 2,445,170 | |
| Proceeds from sales of securities | |
| 1,337,409 | |
| Purchase of securities | |
| (1,637,710 | ) |
| Payments to cover securities borrowed at fair value | |
| | |
| Stock based compensation expense | |
| 324,273 | |
| Changes in operating assets and liabilities: | |
| | |
| Decrease in dividends receivable | |
| 7,087 | |
| Decrease in accrued expenses and other assets | |
| (62,436 | ) |
| Net cash used in operating activities | |
| (2,871,940 | ) |
| | |
| | |
| Cash flows from financing activities: | |
| | |
| Proceeds from margin loan payable | |
| 3,337,615 | |
| Repayment of margin loan payable | |
| (4,568,128 | ) |
| Proceeds from the sale of treasury stock | |
| 4,102,453 | |
| | |
| | |
| Net cash provided by financing activities | |
| 2,871,940 | |
| | |
| | |
| Net change in cash and restricted cash | |
$ | - | |
| Cash and restricted cash at beginning of the year | |
| | |
| Cash and restricted cash at end of the year | |
$ | - | |
| | |
| | |
| Supplemental Disclosures of Cash Flow Information: | |
| | |
| | |
| | |
| Cash paid during the year for: | |
| | |
| | |
| | |
| Income Taxes (State income taxes) | |
$ | 12,209 | |
| | |
| | |
| Interest on margin loan payable | |
$ | 44,466 | |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Financial
Highlights
The
table below sets forth financial data for weighted average shares of stock outstanding for each year and for one share of capital stock
outstanding throughout the years presented. The total investment return does not reflect sales load.
| | |
Six Months Ended | | |
| |
| | |
June 30, 2023 | | |
Year Ended | |
| | |
(Unaudited) | | |
December 31, 2022 | |
| Net Asset Value Per Share, Beginning of Year | |
$ | 6.75 | | |
$ | 5.24 | |
| | |
| | | |
| | |
| Income (loss) from operations: | |
| | | |
| | |
| Net investment (loss) income | |
| (0.10 | ) | |
| (0.24 | ) |
| Net realized and unrealized gain (loss) from investments, options and securities | |
| | | |
| | |
| Borrowed | |
| (0.04 | ) | |
| (0.02 | ) |
| Net realized and unrealized gain from operating division | |
| (0.55 | ) | |
| 1.53 | |
| Other | |
| (0.72 | ) | |
| (0.40 | ) |
| Total (loss) from Operations | |
| (1.41 | ) | |
| 0.87 | |
| | |
| | | |
| | |
| Capital share transactions: | |
| | | |
| | |
| Increase in net assets from stock based compensation | |
| 0.07 | | |
| 0.19 | |
| Increase from sale of treasury stock | |
| 0.92 | | |
| 0.45 | |
| | |
| | | |
| | |
| (Decrease) /increase in Net Asset Value Per Share | |
| (0.42 | ) | |
| 1.51 | |
| | |
| | | |
| | |
| Net Asset Value Per Share, End of Period | |
$ | 6.33 | | |
$ | 6.75 | |
| | |
| | | |
| | |
| Market Price Per Share of Common Stock, Beginning of Year | |
$ | 9.16 | | |
$ | 11.29 | |
| Market Price Per Share of Common Stock, End of Period | |
$ | 9.60 | | |
$ | 9.16 | |
| Change in Price Per Share of Common Stock | |
$ | 0.44 | | |
$ | (2.13 | ) |
| | |
| | | |
| | |
| Total Investment Return | |
| 4.80 | % | |
| (18.87 | )% |
| | |
| | | |
| | |
| Weighted Average Shares Outstanding | |
| 4,463,280 | | |
| 4,083,847 | |
| | |
| | | |
| | |
| Ratios/Supplemental Data | |
| | | |
| | |
| | |
| | | |
| | |
| Net assets, End of Period (in 000’s) | |
$ | 30,359 | | |
$ | 28,969 | |
| | |
| | | |
| | |
| Ratio of total expenses to average net assets | |
| 1.80 | % | |
| 5.86 | % |
| | |
| | | |
| | |
| Ratio of net investment (loss) income after income taxes to average net assets | |
| (1.52 | )% | |
| (4.73 | )% |
| | |
| | | |
| | |
| Portfolio turnover rate | |
| 44.69 | % | |
| 0 | % |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Financial
Highlights (continued)
| | |
Year Ended
December 31, 2021 | | |
Year Ended
December 31, 2020 | | |
Year Ended
December 31, 2019 | |
| | |
| | |
| | |
| |
| Net Asset Value Per Share, Beginning of Year | |
$ | 3.89 | | |
$ | 3.41 | | |
$ | 3.49 | |
| | |
| | | |
| | | |
| | |
| Income (loss) from operations: | |
| | | |
| | | |
| | |
| Net investment (loss) income | |
| (0.20 | ) | |
| (0.08 | ) | |
| (0.03 | ) |
| Net realized and unrealized gain from investments, options and securities Borrowed | |
| 0.21 | | |
| (0.32 | ) | |
| 0.59 | |
| Net realized and unrealized loss from operating division | |
| 1.16 | | |
| 0.11 | | |
| (0.69 | ) |
| Income tax (expense) benefit | |
| 0.00 | | |
| 0.00 | | |
| 0.00 | |
| Other | |
| 0.00 | | |
| 0.01 | | |
| 0.01 | |
| Total income (loss) from Investment Operations | |
| 1.17 | | |
| (0.28 | ) | |
| (0.13 | ) |
| Capital share transactions: | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | |
| Increase in net assets from stock based compensation | |
| 0.18 | | |
| 0.06 | | |
| (0.05 | ) |
| Proceeds from sale of treasury stock and exercise of stock options | |
| - | | |
| 0.70 | | |
| 0.00 | |
| | |
| | | |
| | | |
| | |
| Increase/(Decrease) in Net Asset Value Per Share | |
| 1.35 | | |
| 0.48 | | |
| (0.08 | ) |
| | |
| | | |
| | | |
| | |
| Net Asset Value Per Share, End of Year | |
$ | 5.24 | | |
$ | 3.89 | | |
$ | 3.41 | |
| | |
| | | |
| | | |
| | |
| Market Price Per Share of Common Stock, Beginning of Year | |
$ | 12.50 | | |
$ | 9.40 | | |
$ | 8.20 | |
| Market Price Per Share of Common Stock, End of Year | |
| 11.29 | | |
| 12.50 | | |
| 9.40 | |
| Change in Price Per Share of Common Stock | |
$ | (1.21 | ) | |
$ | 3.10 | | |
$ | 1.20 | |
| | |
| | | |
| | | |
| | |
| Total Investment Return | |
| (9.68 | )% | |
| 32.98 | % | |
| 14.63 | % |
| | |
| | | |
| | | |
| | |
| Weighted Average Shares Outstanding | |
| 4,036,660 | | |
| 3,935,902 | | |
| 3,746,858 | |
| | |
| | | |
| | | |
| | |
| Ratios/Supplemental Data | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | |
| Net assets, End of Year (in 000’s) | |
$ | 21,153 | | |
$ | 15,675 | | |
$ | 12,766 | |
| Ratio of total expenses to average net assets | |
| 7.29 | % | |
| 5.79 | % | |
| 4.26 | % |
| Ratio of net investment (loss) income after income taxes to average net assets | |
| (5.44 | )% | |
| (3.53 | )% | |
| (1.12 | )% |
| Portfolio turnover rate | |
| 0.00 | % | |
| 12.54 | % | |
| 0.00 | % |
The
accompanying notes are an integral part of these financial statements.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
1.
Organization and Investment Objective
Daxor
Corporation (the “Company”) is registered under the Investment Company Act of 1940, as amended, as a diversified, closed-end
management investment company.
The
Company qualifies as a “controlled company” under the listing requirements of the Nasdaq, as the estate of Joseph
Feldschuh, M.D. controls more than 50% of the Company’s voting power, as evidenced by the Company’s ownership records. The
estate owns 53.8% of the outstanding shares. As a result, the estate has the ability to control the outcome on any matter requiring
the approval of shareholders of the Company.
The
Company’s investment goals, objectives and principal strategies are as follows:
| A. | The
Company’s investment goals and objectives are capital preservation, maintaining returns
on capital with a high degree of safety and generating income from dividends and option sales
to help offset operating losses from the Company’s Operating Division. |
| | |
| B. | In
order to achieve these goals, the Company maintains a diversified securities portfolio comprised
primarily of electric utility company common and preferred stocks. The Company also sells
covered calls on portions of its portfolio and also sells puts on stocks it is willing to
own. It also sells uncovered calls and may have net short positions in common stock up to
15% of the value of the portfolio. The net short position is the total fair market value
of the Company’s short positions reduced by the amount due to the Company from the
Broker. If the amount due from the Broker is more than the fair market value of the short
positions, the Company will have a net receivable from the Broker. The Company’s investment
policy is to maintain a minimum of 80% of its portfolio in equity securities of utility companies.
The Board of Directors has authorized this minimum to be temporarily lowered to 70% when
Company management deems it to be necessary. Investments in utilities are primarily in electric
companies. Investments in non-utility stocks will generally not exceed 20% of the value of
the portfolio. |
2.
Significant Accounting Policies
Basis
of Presentation and Use of Estimates
The
Company is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (FASB) Accounting
Standards Codification Topic 946 (ASC 946). The accompanying financial statements were prepared in accordance with accounting principles
generally accepted in the United States of America (“GAAP”), including, but not limited to, ASC 946. GAAP requires the use
of estimates made by management. Management believes that estimates and valuations are appropriate; however, actual results may differ
from those estimates, and the valuations reflected in the accompanying financial statements may differ from the value ultimately realized
upon sale or maturity.
The
following is a summary of significant accounting policies consistently followed by the Company in the preparation of its financial statements.
Valuation
of Investments
The
Company carries its investments in securities at fair value and utilizes various methods to measure the fair value of its investments
on a recurring basis. Fair value is an estimate of the exit price, representing the amount that would be received to sell an asset or
paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair
value measurements are not adjusted for transaction costs. GAAP establishes a hierarchy that prioritizes inputs to valuation methods.
The three levels of inputs are:
Level
1- Unadjusted quoted prices in active markets for identical assets and liabilities that the Company has the ability to access.
Level
2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly
or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments,
interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
Level
3 - Unobservable inputs for an asset or liability, to the extent relevant observable inputs are not available; representing the Company’s
own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best
information available.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
2.
Significant Accounting Policies - (continued)
Valuations
of Investments (continued)
The
availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example,
the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics
particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value
is greatest for instruments categorized in Level 3.
The
inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value
hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant
to the fair value measurement in its entirety. The inputs or methodology used for valuing securities are not necessarily an indication
of the risk associated with investing in those securities.
Investments
in securities, securities borrowed and put and call options that are freely traded and are listed on a national securities exchange are
valued at the last reported sales price on the last business day of the year; securities traded on the over-the-counter market and listed
securities for which no sale was reported on that date are valued at the mean between the last reported bid and asked prices.
The
Company establishes valuation processes and procedures to ensure that the valuation techniques for investments that are categorized within
Level 3 of the fair value hierarchy are fair, consistent, and verifiable. At June 30, 2023, Level 3 investments consist solely of the
Company’s investment in its wholly owned Operating Division at fair value. The Company’s Audit Committee oversees the valuation
process of the Company’s Level 3 investments. The Audit Committee is comprised of members of the Company’s Board of Directors
and is responsible for the valuation processes and procedures and evaluating the overall fairness and consistent application of the valuation
policies. For this valuation process the Audit Committee meets semi-annually or as needed, and in conjunction with reports from an independent
valuation company determines the valuations of the Company’s Level 3 investments. Valuations determined by the Audit Committee
are required to be supported by the independent valuation company whose reports may include information such as market data, third-party
pricing sources; industry accepted pricing models, counterparty prices, or other appropriate methods. On an annual basis, the Company
engages the services of an independent valuation company to perform an independent review of the valuation of the Company’s investment
in its wholly owned Operating Division, and may adjust its valuations based on the recommendations from the valuation firm.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
2.
Significant Accounting Policies - (continued)
Valuation
of Derivative Instruments
The
Company accounts for derivative instruments under FASB ASC 815, “Derivatives and Hedging,” which establishes accounting and
reporting standards requiring that derivative instruments be recorded in the statement of assets and liabilities at fair value. The changes
in the fair values of derivatives are included in the statements of operations as a component of net realized and unrealized loss from
investments.
Investment
Transactions and Income and Expenses
Investment
transactions are accounted for on the trade date. Realized gains and losses on sales of investments are calculated on the basis of identifying
the specific securities delivered. Dividend income and expense are recorded on the ex-dividend date, and interest income is recognized
on the accrual basis. Expenses are recorded on an accrual basis.
Distributions
Net
investment income and net realized gains are accumulated within the Company and used to pay expenses, to make additional investments
or held in cash as a reserve and at the discretion of the Company, to pay dividends to shareholders.
Revenue
Recognition
ACS
Topic 606, Revenue from Contracts with Customers, requires that an entity recognize revenue to depict the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those
goods or services. The guidance requires an entity to follow a five step model to (a) identify the contract(s) with a customer, (b) identify
the performance obligations in the contract, (c) determine the transaction price, (d) allocate the transaction price to the performance
obligations in the contract, and (e) recognize revenue when the entity satisfies a performance obligation.
The
Company recognizes revenues in the Operating Division from product sales when a product is shipped and recognizes revenue from service
contracts as the revenues are earned over the life of service contract and performance obligations are met.
Income
Taxes
The
Company accounts for income taxes under the provisions of FASB ASC 740, “Income Taxes.” This pronouncement requires recognition
of deferred tax assets and liabilities for the estimated future tax consequences of events attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry
forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are
expected to be recovered or settled. The effect on deferred tax assets and liabilities of changes in tax rates is recognized in the statement
of operations in the period in which the enactment rate changes. Deferred tax assets and liabilities are reduced through the establishment
of a valuation allowance at such time as, based on available evidence, it is more likely than not that the deferred tax assets will not
be realized.
The
Company accounts for uncertainties in income taxes under the provisions of FASB ASC 740-10-05, “Accounting for Uncertainties in
Income Taxes”. The ASC clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements.
The ASC prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. The ASC provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosure and transition.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
2.
Significant Accounting Policies - (continued)
Treasury
Stock
Treasury
stock is recorded under the cost method and shown as a reduction of net assets.
3.
Fair Value Measurements of Investments, Financial Instruments and Related Risks
The
following tables summarize the inputs used as of June 30, 2023 for the Company’s assets and liabilities measured at fair value
on a recurring basis at June 30, 2023, categorized by the above mentioned fair value hierarchy and also by denomination:
| Assets | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| Common Stocks | |
$ | 2,616,634 | | |
$ | - | | |
$ | - | | |
$ | 2,616,634 | |
| Preferred Stocks | |
| 351,546 | | |
| - | | |
| - | | |
| 351,546 | |
| Money Market | |
| 1,360,081 | | |
| | | |
| | | |
| 1,360,081 | |
| Investment in Operating Division | |
| - | | |
| - | | |
| 26,000,000 | | |
| 26,000,000 | |
| Total | |
$ | 4,328,261 | | |
$ | - | | |
$ | 26,000,000 | | |
$ | 30,328,261 | |
The
Company purchases equity securities in the form of common and preferred stocks, primarily in the utility sector which historically have
a high degree of safety and pays dividends. The common and preferred stocks are recorded at fair value at the unadjusted closing quoted
price on active securities markets.
Purchased
call and put options: When the Company purchases an option; an amount equal to the premium paid by the Company is recorded as an investment
on the Statement of Assets and Liabilities, the value of which is marked-to-market to reflect the current market value of the option
purchased. If the purchased option expires, the Company realizes a loss equal to the amount of premium paid. When an instrument is purchased
or sold through the exercise of an option, the related premium paid is added to the basis of the instrument acquired or deducted from
the proceeds of the instrument sold. The risk associated with purchasing put and call options is limited to the premium paid.
Written
call and put options: When the Company writes (sells) an option, an amount equal to the premium received by the Company is recorded as
an obligation on the Statement of Assets and Liabilities, the value of which is marked-to-market to reflect the current market value
of the written option. If the written option expires, the Company realizes a gain equal to the amount of premium received. When an instrument
is purchased or sold through the exercise of an option, the related premium received is adjusted to the basis of the instrument acquired
or the instrument sold. The risk associated with writing options is based on the difference between the strike price of the option and
current market price of the underlying security less premium received. See Note 7 for further discussion of Investment and Market Risk
Factors and risks of written call and put options.
Securities
sold short: The Company may sell securities that it does not own, and it will therefore be obligated to purchase such securities at a
future date. The value of the open short position is recorded as a liability, and the Company records an unrealized gain or loss to the
extent of the difference between the proceeds received and the value of the open short position. The Company records a realized gain
or loss when a short position is closed out. By entering into short sales, the Company bears the market risk of increases in the value
of the security sold short in excess of the proceeds received. Possible losses from short sales differ from losses that could be incurred
from purchases of securities because losses from short sales may be unlimited whereas losses from purchases cannot exceed the total amount
invested. See Note 1 regarding the Company’s investment goals and its use of covered positions and Note 7 for further discussion
of Investment and Market Risk Factors.
During
the year ended June 30, 2023, the Company realized proceeds of $1,377,409 from the sale of investment securities.
All
transfers are recognized by the Company at the end of each reporting period. Transfers between Levels 2 and 3 (if any) generally relate
to whether significant unobservable inputs are used for the fair value measurements. See Note 2 – Significant Accounting Policies
for additional information related to the fair value hierarchy and valuation techniques and inputs. During the year ended June 30, 2023
there were no transfers between Levels.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
3.
Fair Value Measurements of Investments, Financial Instruments and Related Risks (continued)
The
following table is a reconciliation of the beginning and ending balances for the Company’s assets measured at fair value on a recurring
basis using significant unobservable inputs (level 3) during the year ended June 30, 2023:
| | |
Balance at
June 30, 2023 | |
| | |
| |
| Balance, December 31, 2022 | |
$ | 26,000,000 | |
| | |
| | |
| Investment in/advances to operating division | |
| 2,445,170 | |
| Realized loss on investment in operating division | |
| (2,445,170 | ) |
| Balance, June 30, 2023 | |
$ | 26,000,000 | |
The
Company’s Level 3 asset consists of its investment in its wholly owned Operating Division at fair value and requires significant
judgment due to the absence of quoted market prices, inherent lack of liquidity, heavy reliance on Level 3 inputs, and the long-term
nature of such investments. Since its inception, the Operating Division has not generated significant revenue and has incurred substantial
operating losses. Due to these substantial losses, the Operating Division has been completely dependent on funding from the Company to
sustain its operations. Investment in Operating Division is primarily located in Oak Ridge, Tennessee and was initially valued at transaction
value for identified assets (property and equipment, land, buildings and laboratory equipment), less accumulated depreciation adjusted
for investment in/advances to operating division, business operations and activity and realized losses. Based on Company initiatives
started in 2016 and through 2022, related to potential partnerships, joint ventures, product development, marketing and other operations
of the Operating Division, the Company hired an independent valuation company to perform a valuation of the Operating Division. The Company
updated the initial 2016 valuation and subsequent valuations at December 31, 2017 through December 31, 2022, using the Income Approach
and Market Approaches as defined in SFAS 157 (ASC Topic 820). Based on the valuation approaches, the valuation ranges were $25,700,000
to $26,300,000 for the blended Income Approach and Market Approach at December 31, 2022. In determining the Income Approach value range,
the Gordon Growth Model valuation technique was used with a discount rate of 20.0% and long-term growth rate of 3.0%. Significant increases
(decreases) in these unobservable inputs in isolation could result in significant changes in fair value measurements. The Income Approach
was weighted 40% given the current financial performance and expectations as to longer-term revenue growth and profitability and a 60%
weight to a recent arm’s length Daxor share sales transactions which raised $2.0 million, resulting in a midpoint of value range
of $26,000,000. Management has reviewed and assessed this valuation and concluded the valuation remains reasonable at June 30,2023.
4.
Derivative Instruments
The
Company may write call and put options in order to generate additional investment income as part of its investment strategy. In the opinion
of management, the use of financial derivative instruments in its investment program is appropriate and customary for the investment
strategies employed reducing certain investment risks. There were no investments in derivative instruments as of June 30, 2023.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
5.
Income Taxes (Benefit)
The
net income tax expense (benefit) for the period ended June 30, 2023 is comprised of the following:
| Current Income Tax Expense (Benefit): | |
| | |
| Federal | |
$ | - | |
| State and local | |
| - | |
| Total current income tax expense (benefit) | |
| - | |
| Deferred Tax Expense: | |
| | |
| Federal | |
$ | - | |
| State and local | |
| - | |
| Total deferred tax expense | |
| - | |
| Net income tax (benefit) | |
$ | - | |
The
Company has a net operating loss carry forward of approximately $31,965,810 at June 30, 2023. Approximately $16,744,764 of these losses
relate to years prior to 2018 and will begin to expire in 2033. Approximately $15,221,046 of these losses relates to the years 2018 through
2022, and will not expire, but are subject to limitations on usage.
The
following table sets forth the net operating loss carry forwards by state and local jurisdiction at June 30, 2023:
| New York State | |
$ | 4,728,155 | |
| New York City | |
$ | 6,741,134 | |
| California | |
$ | 2,371,705 | |
| Tennessee | |
$ | 7,704,435 | |
| South Carolina | |
$ | 9,635,570 | |
At
June 30, 2023, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The
Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes
interest and penalties related to uncertain tax positions in investment administrative expenses. As of June 30, 2023, the Company has
not recorded any provisions for accrued interest and penalties related to uncertain tax positions.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
5.
Income Taxes (Benefit) - (continued)
In
certain cases, the Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant
tax authorities. The Company files federal, state and local income tax returns in jurisdictions with varying statutes of limitations.
The 2016 through 2022 tax years generally remain subject to examination by federal, state and local tax authorities.
Under
Internal revenue code section 542, a company is defined as a Personal Holding Company (“PHC”) if it meets both an ownership
test and an income test. The ownership test is met if a company has five or fewer shareholders that own more than 50% of the company,
which is applicable to Daxor. The income test is met if PHC income items such as dividends, interest and rents exceed 60% of adjusted
ordinary gross income. Adjusted ordinary income is defined as all items of income except capital gains. For the year ended June 30, 2023,
more than 60% of Daxor’s adjusted gross income came from items defined as PHC income.
Determining
the PHC tax liability requires computing Daxor’s “undistributed PHC income” and taxing such PHC income at the statutory
rate of 20%. Undistributed PHC income is current year taxable income of the Company, exclusive of the net operating loss carry forward
deduction that is allowed for regular tax purposes. The Company incurred no liability for PHC for the period ended June 30, 2023 due
to the net operating losses applied to realized gains incurred during the year.
| Computed expected provision at statutory rates | |
| (21.0 | )% |
| Valuation allowance | |
| (13.4 | )% |
| State taxes | |
| (0.5 | )% |
| Non-deductible/non-taxable and other items | |
| 36.3 | % |
| Dividend received deduction and other items | |
| (1.4 | )% |
| | |
| | |
| Effective income tax (benefit) rate | |
| 0.0 | % |
6.
Deferred Income Taxes
Deferred
income taxes result from differences in the recognition of gains and losses on marketable securities; stock options, as well as from
carry forwards of the Company’s net operating losses of approximately $31,965,810 at June 30, 2023, and tax credits of approximately
$1,528,433 for tax purposes. At June 30, 2023 the aggregate cost of investments for federal income tax purposes was $5,489,843.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
6.
Deferred Income Taxes - (continued)
The
significant components of deferred tax assets and liabilities are reflected in the following table:
| Unrealized gains on investments in securities | |
$ | (462,484 | ) |
| Unrealized gain on investment in operating division | |
| (5,537,458 | ) |
| Net operating loss-carry forward | |
| 7,477,080 | |
| Net capital loss carry forward | |
| (289,300 | ) |
| Business tax credits carried forward | |
| 1,528,433 | |
| Others | |
| 51,511 | |
| Deferred Income Tax Available for use | |
| 2,767,782 | |
| Valuation allowance | |
| (2,767,782 | ) |
| Net Deferred Tax Asset | |
$ | - | |
Realization
of deferred tax assets is dependent on future earnings. Due to the uncertainty of the realization of its net deferred tax assets, the
Company has provided a valuation allowance. In assessing the potential to realize the deferred tax asset, management considers whether
it is more likely than not that some or perhaps all of the deferred tax assets will be realized. The ultimate realization of deferred
tax assets is dependent upon the generation of future taxable income during the periods in which these temporary differences become deductible.
Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies
in making their assessment. The Company recorded a valuation allowance of $2,767,782 at June 31, 2023. The valuation allowance increased
$179,646 from December 31, 2022. If the Company becomes profitable before the expiration of the loss carry forwards, it would have the
ability to utilize them in order to offset any taxable income.
7.
Investment and Market Risk Factors
The
Company enters into investments in securities, call and put options and securities borrowed and/or financial instruments that may have
off balance sheet risks, where the potential loss due to changes in the market (market risk), failure of counterparty to perform on the
transaction risk (credit risk) and other risk elements, such as interest rate risk, exceeds the value and/or obligations of such financial
instruments. It is the Company’s general policy to mitigate such risks by transacting with established counterparties. The Company
transacts with and custodies investment assets at UBS Financial Services, Inc. (“Broker”).
The
Company’s investments in securities arise from investments in long common and preferred stocks, selling common stocks short and
transacting in put and call (naked and covered) options. These investments are subject to equity risks of increases and decreases in
market exchange prices such as on the Nasdaq.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
7.
Investment and Market Risk Factors - (continued)
The
Company is subject to certain inherent risks arising from its investing activities of selling securities short and writing put and call
options. Selling securities short creates an obligation to purchase the securities at an unknown future date, subject to the Company’s
discretion, at the then prevailing future market prices. Securities borrowed create the risk that the ultimate obligation may exceed
the liability reflected in these financial statements.
The
Company collects premiums and the opportunity to create option premium income when writing put and call options if the options expire
out-of-the-money. Writing put and call options gives the option buyer the right to exercise the option against the option writer. Writing
put options obligates the writer to purchase the stock at the strike price if the stocks’ current market price is below the strike
price prior to expiration of the put option. The potential loss in writing a put option is the strike price less the premium collected
if the stock price falls to zero. Writing call options obligates the writer to sell the stock at the strike price if the stock’s
current market price is greater than the strike price prior to expiration of the call option. The potential loss in writing a naked call
option is unlimited as the rise of a stock price is unlimited. The potential loss in writing a covered call is limited to the strike
price less the cost of the underlying security the Company holds in the portfolio. The Company endeavors to write covered calls but may
also write naked calls.
Cash
receivable from broker and margin loans payable reflect accounts with the Company’s Broker. Due from broker represents amounts
receivable from brokers that are available for investing but have not been invested. Margin loan payable represents obligations to the
Broker for leveraging investments in securities. Investments in securities are collateral for the margin loan payable. The Company does
not have the right of setoff nor netting agreements between brokers.
The
Company’s investments may be subject to changes in interest rates as they may affect equity and option markets. Interest rate risk
refers to the fluctuations in value of fixed-income securities resulting from the inverse relationship between price and yield. For example,
an increase in general interest rates will tend to reduce the market value of already issued fixed-income investments, and a decline
in general interest rates will tend to increase their value. In addition, debt securities with longer maturities, which tend to have
higher yields, are subject to potentially greater fluctuations in value from changes in interest rates than obligations with shorter
maturities.
The
Company is subject to volatility risk which refers to the magnitude of the movement, but not the direction of the movement, in a financial
instrument’s price over a defined time period. Large increases or decreases in a financial instrument’s price over a relative
time period typically indicate greater volatility risk, while small increases or decreases in its price typically indicate lower volatility
risk.
Legal,
tax and regulatory changes continue to occur in the United States and globally, additionally, regulatory environments, as a whole, continue
to evolve and change. The effect of any future legal, tax and/or regulatory changes are unknown and could be substantial and adverse.
8.
Related Party Transactions
The
Company reported $64,333 of portfolio administrative expenses which is included in investment administrative charges on the Statement
of Operations for the six-month period ended June 30, 2023. These charges represent a portion of the payroll and related expenses of
two (2) employees of the Operating Division for services performed for the Company.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
9.
Margin Loan
As
of June 30, 2023 the Company was not utilizing the margin loan facility available. The Company has available a facility that is secured
by the Company’s investments in marketable securities. The Company utilized the facility during the six month period ended June
30, 2023 and the interest expense on the margin loan for the six month period ended June 30, 2023 was $44,466. The ability of the Company
to incur margin debt at any given time is based on the current amount outstanding and the market value of the portfolio of marketable
securities. There are no set repayment terms for the Company’s margin loan.
The
following table summarizes the margin loan activity for the year ended June 30, 2023:
| Balance at 6/30/23 | | |
Interest
rate at
6/30/23 | |
Maximum
amount
outstanding during
the six months ended
June 30, 2023 | | |
Average
amount
outstanding
during the
six-months ended
June 30, 2023 | | |
Weighted average interest
rate during the six months
ended June 30, 2023 | |
| $ | -0- | | |
|
N/A |
| |
$ | 2,438,635 | | |
$ | 1,011,753 | | |
| 5.720 | % |
10.
Capital Stock
At
June 30, 2023, there were 10,000,000 shares of $0.01 par value capital stock authorized. The paid in capital of $13,278,406 at June 30,
2023 consists of the following amounts:
| Additional Paid in Capital in excess of par value of common Stock | |
$ | 13,225,240 | |
| Common Stock | |
| 53,166 | |
| Total Paid in Capital | |
$ | 13,278,406 | |
11.
Treasury Stock
The
Company’s Board of Directors from time to time has authorized the repurchase of shares of the Company’s common stock in the
open market usually as funds are available and if the stock is trading at a price which management feels is undervalued. The Company
did not repurchase any shares of the Company during the six months ended June 30, 2023. The Company sold 464,599 shares of treasury stock
in May and June 2023 for net proceeds to the Company of $4,102,453.
Treasury stock at Jun 30, 2023:
| Treasury Stock at repurchase price | |
$ | 4,668,572 | |
| Treasury Stock shares | |
| 524,211 | |
12.
Dividends
In
2008, management instituted a policy of paying dividends when funds are available. The Company did not declare a dividend for six-months
ended June 30, 2023.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
13.
Stock Options
In
June 2019, the Board of Directors of the Company approved the Daxor Corporation 2020 Incentive Compensation Plan (the “2020 Plan”).
In April 2020 the Company received exemptive relief from the Securities & Exchange Commission (“SEC”) and The 2020 Plan
was given approval to become operational effective in April, 2020. The 2020 Plan was approved by shareholders of the Company on June
25, 2020. In addition to Stock Options, awards under the 2020 Plan can consist of Stock Appreciation Rights, Restricted Stock, Restricted
Stock Units, Deferred Stock Units, Cash Awards and Bonus Stock (collectively, “Stock Awards”). The 2020 Plan is an effort
to provide incentive to employees, officers, agents, consultants, and independent contractors through proprietary interest. The Board
of Directors acts as the Plan Administrator, and may issue these Stock Awards at its discretion.
The
2020 Plan replaced the 2004 Stock Option Plan.
The
maximum number of shares that may be issued under the 2020 Plan is 250,000 or 5% of the Company’s outstanding shares, whichever
is greater. The Company has obtained approval from shareholders to increase the number of shares available for issuance from 250,000
shares to 400,000 shares (or such lesser amount as may be determined by the Company), subject to the SEC granting an exemptive order
to permit the operation of the 2020 Plan as amended, and the SEC may not elect to grant such order. Under the provisions of the 2020
Plan, the exercise price of any stock options issued is a minimum of 100% of the closing market price of the Company’s stock on
the grant date of the option. Previously, the Company issued options to various employees under the previous 2004 Stock Option Plan and
the Stock Option Plan that was also administered by the Board of Directors. All issuances have varying vesting and expiration timelines.
As of June 30, 2023 the 2020 Plan had 206,220 options outstanding and 149,228 were exercisable. The 2004 Stock Option Plan had 37,216
options outstanding and 37,216 were exercisable. The Company has not granted options under the 2004 Stock Option Plan since August 2018.
The 2004 Stock Option Plan ceased operation upon approval of the 2020 Plan, although stock options that were awarded under the 2004 Plan
that have not expired are still eligible to be exercised.
At
June 30, 2023, there was $1,745,712 of unvested stock-based compensation expense to recognize. The Company recognized $324,273 of stock-based
compensation expense, which is included in investment administrative charges in the Statement of Operations for six month period ended
June 30, 2023. There was no aggregate intrinsic value at June 30, 2023 as the closing price of the Company’s stock was lower than
the average exercise price of the underlying options. The intrinsic value is calculated based on the difference between the closing market
price of the Company’s common stock and the exercise price of the underlying options.
To
calculate the option-based compensation, the Company used the Black-Scholes option-pricing model. The Company’s determination of
fair value of option-based awards on the date of grant using the Black-Scholes model is affected by the Company’s stock price as
well as assumptions regarding a number of subjective variables. These variables include, but are not limited to, the Company’s
expected stock price volatility over the term of the awards, risk-free interest rate, and the expected life of the options. The risk-free
interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. The expected volatility,
holding period, and forfeitures of options are based on historical experience.
For
the six month period ended June 30, 2023, 20,072 stock options were granted to employees, Directors and outside consultants from the
2020 Plan with a weighted average exercise price of $9.48. The stock options granted during the six month period ended June 30, 2023
from the 2020 Plan are still outstanding and 149,228 stock options have vested as of June 30, 2023.
The
fair values of stock options granted in the six month period ended June 30, 2023 were estimated using the Black-Scholes option-pricing
model with the following assumptions for the six month period ended June 30, 2023.
| | |
Six
Months
June 2023 | |
| Risk free rate | |
| 4.74 | % |
| Expected life (in years) | |
| 4.79 | |
| Expected volatility | |
| 53.43 | % |
| Dividend yield | |
| 0.00 | % |
| | |
| | |
| Weighted Average grant date fair value per share | |
$ | 9.48 | |
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
13.
Stock Options - (continued)
The
details of option activity for the 2020 Plan for the year ended June 30, 2023 is as follows:
| | |
Number of Shares | | |
Weighted Average
Exercise Price | |
| Outstanding and Exercisable, January 1, 2023 | |
| 256,501 | | |
$ | 13.27 | |
| Granted | |
| 20,072 | | |
$ | 9.48 | |
| Canceled | |
| (70,353 | ) | |
$ | (13.83 | ) |
| Expired | |
| - | | |
| - | |
| Outstanding at June 30, 2023 | |
| 206,220 | | |
$ | 12.99 | |
The
following tables summarize information concerning currently outstanding and exercisable options at June 30, 2023:
| Range
of Exercise Prices | | |
Number
Outstanding at
June 30, 2023 | | |
Weighted
Average Remaining
Contractual Life at
June 30, 2023 | | |
Weighted
Average Exercise Price
at June 30, 2022 | |
| $ | 8.30 - $18.95 | | |
| 206,220 | | |
| 4.06
years | | |
$ | 12.99 | |
| Range of Exercise Prices | | |
Number
Exercisable at
June 30, 2023 | | |
Weighted
Average
Exercise Price at
June 30, 2023 | |
| $ | 8.83 - $18.95 | | |
| 149,228 | | |
$ | 13.57 | |
The
details of employee option activity for the 2004 Stock Option Plan for the year ended June 30, 2023 is as follows:
| | |
Number of Shares | | |
Weighted Average
Exercise Price | |
| | |
| | |
| |
| Outstanding and Exercisable, January 1, 2023 | |
| 147,066 | | |
$ | 8.47 | |
| Granted | |
| - | | |
| - | |
| Exercised | |
| (13,500 | ) | |
$ | (4.72 | ) |
| Expired | |
| (53,600 | ) | |
$ | (9.11 | ) |
| Canceled | |
| (42,750 | ) | |
$ | (8.43 | ) |
| Outstanding at June 30, 2023 | |
| 37,216 | | |
$ | 8.94 | |
The
following tables summarize information concerning currently outstanding and exercisable options from the 2004 Stock Option Plan at June
30, 2023:
| Range of Exercise Prices | | |
Number
Outstanding at
June 30, 2023 | | |
Weighted
Average
Remaining
Contractual Life
at June 30, 2023 | | |
Weighted
Average
Exercise Price
at June 30, 2023 | |
| | Below - $9.52 | | |
| 37,216 | | |
| 0.48 years | | |
$ | 8.47 | |
| Range of Exercise Prices | | |
Number
Exercisable at
June 30, 2023 | | |
Weighted
Average
Exercise
Price at
June 30, 2023 | |
| | Below - $9.52 | | |
| 37,216 | | |
$ | 8.47 | |
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
The
following table summarizes information about restricted stock transactions:
| | |
Six Months Ended
June 30, 2023 | | |
Weighted
Average
Grant Date Fair Value | |
| | |
| | |
| |
| Unvested at the beginning of the year | |
| 9,813 | | |
$ | 10.98 | |
| Awards granted | |
| 12,446 | | |
$ | 9.76 | |
| Vested | |
| (14,269 | ) | |
$ | (10.07 | ) |
| Unvested at the end of the period | |
| 7,990 | | |
$ | 10.70 | |
14.
Commitments
The
Company does not have any significant commitments.
Daxor
Corporation
Notes
to Financial Statements
June
30, 2023 (Unaudited)
15.
Registration Statement
The
Company has filed a Form N-2 Registration Statement under the Securities Act of 1933, pursuant to general instruction A.2 of form N-2
which permits the Company to raise additional equity capital by issuing additional shares of common stock from time to time in varying
amounts and by different offering methods, at prices and on terms to be determined by market conditions at the time of offering. During
any 12-month period, the aggregate market value of securities the Company may offer may not exceed one third of the aggregate market
value of voting and non-voting common equity held by persons who are not affiliates of the Company. The Registration Statement became
effective July 16, 2021.
16.
Subsequent Events
Nothing
to report as of this date.
Daxor
Corporation
Supplemental
Data
General
Investment
Products Offered
| ● | Are
not FDIC Insured |
| ● | May
Lose Value |
| ● | Are
Not Bank Guaranteed |
The
investment return and principal value of an investment in Daxor Corporation will fluctuate in part as the prices of the individual securities
in which it invests fluctuate, so that your shares, when sold, may be worth more or less than their original cost. You should consider
the investment objectives, risks, charges and expenses of Daxor and Daxor’s operating business carefully before investing. For
a free copy of the Company’s definitive prospectus (when available), which contains this and other information, call the Company
at 212- 330-8500.
This
shareholder report must be preceded or accompanied by the Company’s prospectus for individuals who are not current shareholders
of the Company.
Voting
Proxies on Portfolio Securities
A
description of the policies and procedures that the Company uses to determine how to vote proxies relating to portfolio securities owned
by the Company and the Company’s proxy voting record for the 12-month period ended June 30, 2023 are available (i) without charge,
upon request, by calling 1-212-330-8500 and (ii) on the Securities and Exchange Commission’s website: www.sec.gov.
Disclosure
of Portfolio Holdings
The
SEC has adopted the requirement that all investment companies file a complete schedule of investments with the SEC for their first and
third fiscal quarters on Form N-PORT. The Company’s Form N-PORT for March 31, 2023 reporting portfolio securities held by the Company,
is available on the Commission’s website at http://www.sec.gov, and may be reviewed and copied at the Commission’s Public
Reference Room in Washington, DC. Information on the operation of the public reference room may be obtained by calling 800-SEC-0330.
Shareholder
Vote
The
Company’s Annual Meeting was held July 11, 2023. At the Annual Meeting, the following directors were elected for terms expiring
at the annual meeting of shareholders to be held in 2024 by the votes indicated:
| | |
For | | |
Withheld | | |
Broker Non-votes | |
| James Lombard | |
| 3,498,907 | | |
| 87,254 | | |
| -0- | |
| Henry D. Cremisi, MD | |
| 3,500,783 | | |
| 85,378 | | |
| -0- | |
| Edward Feuer | |
| 3,500,783 | | |
| 85,378 | | |
| -0- | |
| Joy Goudie, Esq. | |
| 3,500,783 | | |
| 85,378 | | |
| -0- | |
| Michael Feldschuh | |
| 3,505,372 | | |
| 80,789 | | |
| -0- | |
| Jonathan Feldschuh | |
| 3,485,491 | | |
| 100,670 | | |
| -0- | |
| Caleb DesRosiers, Esq. | |
| 3,508,783 | | |
| 77,378 | | |
| -0- | |
The
following reflects the voting results for matters other than the election of directors brought for vote at the Annual Meeting:
| | |
For | | |
Against | | |
Abstain | | |
Broker Non-votes | |
| Ratification of Steven Zelin, CPA, LLC as Daxor Corporation’s | |
| | | |
| | | |
| | | |
| | |
| independent registered public accounting firm | |
| 3,568,964 | | |
| 16,671 | | |
| 526 | | |
| -0- | |
Daxor
Corporation
Privacy
Policy
The
Company and Your Personal Privacy-
Daxor
Corporation is an investment company registered with the Securities and Exchange Commission under the Investment Company Act of 1940.
What
Kind of Non-Public Information do we Collect About you if you Become a Shareholder?
Daxor
Corporation does not collect non-public information about our shareholders.
What
Information do we disclose and to whom do we disclose it?
We
do not disclose any non-public personal information about our customers or former customers of our operating division to anyone, other
than our service providers who need to know such information and as otherwise permitted by law. If you want to find out what the law
permits, you can read the privacy rules adopted by the Securities and Exchange Commission. They are in volume 17 of the Code of Federal
Regulations, Part 248. The Commission often posts information about its regulations on its website, www.sec.gov.
What
do we do to protect Your Personal Information?
We
restrict access to non-public personal information about our customers or former customers to the people who need to know that information
in order to perform their jobs or provide services to you. We maintain physical, electronic, and procedural safeguards to keep your personal
information confidential.
Daxor
Corporation
About
the Corporation’s Directors and Officers
The
Corporation is governed by a Board of Directors that meets to review investments, performance, expenses and other business matters, and
is responsible for protecting the interests of shareholders. The majority of the Corporation’s directors are independent of Daxor
Corporation.; the only “inside” directors is an officer and a director of Daxor Corporation. The Board of Directors elects
the Corporation’s officers, who are listed in the table. The business address of each director and officer is 109 Meco Lane, Oak
Ridge, TN 37830.
Name,
Address
and Age | |
Position(s)
Held
with Company | |
Term
of Office
And
Length of Time
Served | |
Principal
Occupation(s)
During Past Five
Years | |
Number
of
Portfolios
Overseen by
Director | |
Other
Directorships
Held
(during past
five years) by
Director |
| “Noninterested Persons” | |
| |
| |
| |
| |
|
| | |
| |
| |
| |
| |
|
| | |
| |
| |
| |
| |
|
| James Lombard | |
| |
| |
Director of | |
| |
|
| 109 Meco Lane | |
| |
| |
Administrative | |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
Services Division,
New York City | |
| |
|
| | |
| |
Director | |
Council | |
| |
|
| Age: 88 | |
Director | |
since 1989 | |
(Retired). | |
None | |
None |
| | |
| |
| |
| |
| |
|
| Henry D. Cremisi, MD | |
| |
| |
| |
| |
|
| FACP | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
Medical Director,
AstraZeneca, a | |
| |
|
| | |
| |
Director | |
Pharmaceutical | |
| |
|
| Age: 65 | |
Director | |
since 2020 | |
company | |
None | |
None |
| | |
| |
| |
| |
| |
|
| Edward Feuer | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
Managing Partner,
Feuer | |
| |
|
| | |
| |
Director | |
& Orlando, LLP, an | |
| |
|
| Age: 67 | |
Director | |
since 2016 | |
accounting firm | |
None | |
None |
| | |
| |
| |
| |
| |
|
| Joy Goudie, Esq. | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
| |
| |
|
| | |
| |
Director | |
Registered Patent | |
| |
|
| Age: 66 | |
Director | |
since 2020 | |
Attorney | |
None | |
None |
| | |
| |
| |
| |
| |
|
| Caleb DesRosiers | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
| |
| |
| |
|
| | |
| |
One Year Term, | |
| |
| |
|
| Age: 50 | |
Director | |
Director since 2022 | |
Attorney | |
None | |
None |
Name,
Address
and Age | |
Position(s)
Held
with Company | |
Term
of Office
And
Length of Time
Served | |
Principal
Occupation(s)
During Past Five
Years | |
Number
of
Portfolios
Overseen by
Director | |
Other
Directorships
Held
(during past
five years) by
Director |
| “Interested Persons” | |
| |
| |
| |
| |
|
| | |
| |
| |
| |
| |
|
| Michael Feldschuh | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
Executive Vice
President | |
| |
|
| | |
| |
Director | |
Chairman, President, | |
| |
|
| Age: 53 | |
Director | |
since 2013 | |
CEO | |
One | |
None |
| | |
| |
| |
| |
| |
|
| Jonathan Feldschuh | |
| |
| |
| |
| |
|
| 109 Meco Lane | |
| |
| |
| |
| |
|
| Oak Ridge, TN 37830 | |
| |
One year term, | |
| |
| |
|
| | |
| |
Director | |
Chief Scientific | |
| |
|
| Age 58 | |
Director | |
since 2017 | |
Officer | |
None | |
None |
The
Daxor’s Statement of Additional Information includes additional information about the Directors and is available free of charge,
upon request, by calling toll-free at 212-330-8500.
Daxor
Corporation
June
30, 2023 (Unaudited)
ITEM
2. CODE OF ETHICS
The
information required by this Item in only required in annual report on this Form N-CSR
ITEM
3. AUDIT COMMITTEE FINANCIAL EXPERT
The
information required by this Item in only required in annual report on this Form N-CSR
ITEM
4. PRINCIPAL ACCOUNTATN FEES AND SERVICES
The
information required by this Item in only required in annual report on this Form N-CSR
ITEM
5. AUDIT COMMITTEE OF LISTED REGISTRANTS.
The
information required by this Item in only required in annual report on this Form N-CSR
ITEM
6. SCHEDULE OF INVESTMENTS
Included
herein under Item 1.
ITEM
7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.
The
information required by this Item in only required in annual report on this Form N-CSR
ITEM
8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES
| (a) | The
information required by this Item in only required in annual report on this Form N-CSR |
Daxor
does not have an outside portfolio manager. The Chief Executive Officer of the Company, Michael Feldschuh, manages Daxor’s portfolio.
| (b) | There
has been no change as of the date of the filing of this N-CSR, to any of the portfolio managers
identified in response to this item in the Registrant’s most recent annual report on
Form N-CSR. |
ITEM
9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS.
None
ITEM
10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
There
have been no material changes to the procedures by which shareholders may recommend nominees to the Company’s Board of Directors.
ITEM
11. CONTROLS AND PROCEDURES.
(a)
The certifying officers, whose certifications are included herewith, have evaluated the registrant’s disclosure controls and
procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) within 90
days of this report. Deficiencies in the registrant’s disclosure controls and procedures were not adequately designed and
operating effectively to ensure that information required to be disclosed by the registrant in the reports it files or submits under
the 1940 Act and Securities Exchange Act of 1934 was recorded, processed, summarized and reported in a timely fashion within the
time periods specified in the Securities and Exchange Commission’s rules and forms. Management has taken corrective steps to
resolve these matters so that future reporting may take place within the specified time frame of the 1940 Act.
(b)
There were no significant changes in the registrant’s internal control over financial reporting that occurred during the
registrant’s last fiscal half-year that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting other than the above mentioned corrective steps to improve the
timeliness of financial reports as required under the 1940 Act.
ITEM
12. DISCLOSURE OF SECURITIES LENDING ACTIVITIES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.
Daxor
did not lend out portfolio securities.
ITEM
13. EXHIBITS.
(a)(2)
A separate certification for the principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a)
under the Investment Company Act of 1940, as amended (17 CFR 270.30a-2(a)) is filed herewith.
(b)
Officer certifications as required by Rule 30a-2(b) under the Investment Company Act of 1940, as amended (17 CFR 270.30a-2(b)) also
accompany this filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Registrant)
Daxor Corporation
By
(Signature and Title) /s/ Michael Feldschuh
Michael
Feldschuh
President
and Chief Executive Officer (Principal Executive Officer)
Date:
August 28, 2023
Pursuant
to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below
by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By
(Signature and Title) /s/ Michael Feldschuh
Michael
Feldschuh
President
and Chief Executive Officer (Principal Executive Officer)
Date:
August 28, 2023
By
(Signature and Title) /s/ Robert J. Michel
Robert
J. Michel
Chief
Financial Officer and Chief Compliance Officer (Principal Financial Officer)
Date:
August 28, 2023
Exhibit
13(a)(2)
CERTIFICATION
Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002
I,
Michael Feldschuh, certify that:
| 1. | I
have reviewed this report on Form N-CSR of Daxor Corporation |
| | |
| 2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered
by this report; |
| | |
| 3. | Based
on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations,
changes in net assets, and cash flows (if the financial statements are required to include
a statement of cash flows) of the registrant as of, and for, the periods presented in this
report; |
| | |
| 4. | I
am responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the
registrant and have: |
| (a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared; |
| | | |
| (b) | Designed
such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles; |
| | | |
| (c) | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of a date within 90 days prior to the filing date of this report based on such evaluation;
and |
| | | |
| (d) | Disclosed
in this report any change in the registrant’s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and |
| 5. | I
have disclosed to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): |
| (a) | All
significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize, and report financial information; and |
| | | |
| (b) | Any
fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
| By: |
/s/
Michael Feldschuh |
|
| |
Michael
Feldschuh |
|
| |
President
(Chief Executive Officer, Principal Executive Officer) |
|
Date:
August 28, 2023
Exhibit
13(a)(2)
CERTIFICATION
Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002
I,
Robert J. Michel, certify that:
| 1. | I
have reviewed this report on Form N-CSR of Daxor Corporation |
| | |
| 2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered
by this report; |
| | |
| 3. | Based
on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations,
changes in net assets, and cash flows (if the financial statements are required to include
a statement of cash flows) of the registrant as of, and for, the periods presented in this
report; |
| | |
| 4. | I
am responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the
registrant and have: |
| (a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared; |
| | | |
| (b) | Designed
such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles; |
| | | |
| (c) | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of a date within 90 days prior to the filing date of this report based on such evaluation;
and |
| | | |
| (d) | Disclosed
in this report any change in the registrant’s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and |
| 5. | I
have disclosed to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): |
| (a) | All
significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize, and report financial information; and |
| | | |
| (b) | Any
fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
| By: |
/s/
Robert J. Michel |
|
| |
Robert
J. Michel |
|
| |
Chief
Financial Officer (Chief Principal Financial Officer/Principal Accounting Officer/Chief Compliance Officer) |
|
Date:
August 28, 2023
Exhibit
13(b)
CERTIFICATION
Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a)
and (b) of section 1350, chapter 63 of title 18, United States Code)
In
connection with the attached report of Daxor Corporation on Form N-CSR to be filed with the Securities and Exchange Commission (the “Report”),
the undersigned officer of the Corporation does hereby certify that, to the best of such officer’s knowledge:
1.
The Report fully complies with the requirements of 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company as of, and for, the periods presented in the Report.
This
certification is furnished as an exhibit solely pursuant to Item 12(b) of Form N-CSR and is not deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. This
certification is not deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended or the Securities
Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this certification by reference.
| By: |
/s/
Michael Feldschuh |
|
| |
Michael
Feldschuh |
|
| |
President
(Chief Executive Officer, Principal Executive Officer) |
|
Date:
August 28, 2023
Exhibit
13(b)
CERTIFICATION
Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections
(a)
and (b) of section 1350, chapter 63 of title 18, United States Code)
In
connection with the attached report of Daxor Corporation on Form N-CSR to be filed with the Securities and Exchange Commission (the “Report”),
the undersigned officer of the Corporation does hereby certify that, to the best of such officer’s knowledge:
1.
The Report fully complies with the requirements of 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company as of, and for, the periods presented in the Report.
This
certification is furnished as an exhibit solely pursuant to Item 12(b) of Form N-CSR and is not deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. This
certification is not deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended or the Securities
Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this certification by reference.
| By: |
/s/
Robert J. Michel |
|
| |
Robert
J. Michel |
|
| |
Chief
Financial Officer (Chief Principal Financial Officer/Principal Accounting
Officer/Chief Compliance Officer) |
|
Date:
August 28, 2023
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Apr 2024 to May 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2023 to May 2024
